A simple blood test to choose the best treatment for each patient with depression.

Project description

A blood test for antidepressant medication choice

Treatment of major depressive disorder is based on a trial-and-error approach, with patients trying several different medications and often without the desired response. This has a huge socioeconomic impact affecting millions of people who struggle to recover. Funded by the European Innovation Council, the RxMine project introduces a novel platform to assist the search of the best antidepressant for each patient. The process involves the analysis of a patient blood sample to predict the individual response to various medications. It is based on a brain-in-a-dish model that allows high-throughput screening of available drugs and machine learning to identify the most effective choice in a fast and effortless way.

Fields of science

• natural sciences › biological sciences › neurobiology
• natural sciences › biological sciences › genetics
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• medical and health sciences › medical biotechnology › cells technologies › stem cells
• engineering and technology › medical engineering › medical laboratory technology › laboratory samples analysis
• natural sciences › computer and information sciences › artificial intelligence › machine learning

Programme(s)

• HORIZON.3.1 - The European Innovation Council (EIC) Main Programme

Topic(s)

• HORIZON-EIC-2022-ACCELERATOROPEN-01 - EIC Accelerator Open

Call for proposal

HORIZON-EIC-2022-ACCELERATOR-01

See other projects for this call

Funding Scheme

HORIZON-AG - HORIZON Action Grant Budget-Based

Coordinator

GENETIKAPLUS LTD

Net EU contribution

€ 2 499 000,00

Address

126 Yigal Alon Street
6744332 Tel Aviv
Israel

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 1 071 000,00